Another extraordinary company in the American market that is absolutely undervalued according to its strong balance sheets. Nothing happens by chance, but rather for lack of a basic behavioral and rational approach on the part of individuals who act with extreme greed and also ignorance. The Company I am presenting is 40% (or more) below … Continue reading Undervalued Biopharmaceutical Giant | Stocks Series .9
Based on the last charts collected, referring to the S&P 500 and NYSE indices, we were able to acquire some rational interpretations that help us to make decisions. I'm not talking about selling anything, however, we managed to remain calm and practice the wisdom to look for Value Companies still with Fair Prices. FOLLOW THE … Continue reading Weekly Report | Personal Vision
Getting rid of the "common paths" of the markets has great benefits. This is because the individual moves away from the herd effect; acquires larger volumes of shares of companies that no one cares about at bargain prices and values its equity when every market sees Value in this Company. There are several reports over … Continue reading Very Cheap Japanese Bank | Series .6 Stocks
Weekly Summary Report on the evolution - or involution - of Markets. There are 5 (five) graphs that demonstrate greater absolute detachments that exist in the pricing of the S&P500 in relation to the reality of the general economy. Consumption gradually retracted while the expectation of rising assets remains intense. Yesterday, 30/09/2021, the largest withdrawal … Continue reading The Great Break | Chance Of A Life?
No último post abri minha ideia sobre a empresa de biotecnologia que desenvolve a última geração no tratamento do câncer uretral e renal. Hoje, a mesma empresa divulgou seus últimos resultados em seus tratamentos. BOOM!! Os dados finais do ensaio de Fase 2b OPTIMA II do UGN-102 mostraram resposta completa e durável para instilação intravesical … Continue reading BREAK NEWS: Resultados da American Urological Association 2021